Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Synthesis and CYP24A1 inhibitory activity of N-(2-(1H-imidazol-1-yl)-2-phenylethyl)arylamides.

Aboraia AS, Yee SW, Gomaa MS, Shah N, Robotham AC, Makowski B, Prosser D, Brancale A, Jones G, Simons C.

Bioorg Med Chem. 2010 Jul 15;18(14):4939-46. doi: 10.1016/j.bmc.2010.06.011. Epub 2010 Jun 9.

PMID:
20594862
2.

Synthesis and CYP24A1 inhibitory activity of (E)-2-(2-substituted benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralones.

Aboraia AS, Makowski B, Bahja A, Prosser D, Brancale A, Jones G, Simons C.

Eur J Med Chem. 2010 Oct;45(10):4427-34. doi: 10.1016/j.ejmech.2010.07.001. Epub 2010 Jul 8.

PMID:
20655626
3.
4.

Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators.

Pettersson M, Johnson DS, Subramanyam C, Bales KR, am Ende CW, Fish BA, Green ME, Kauffman GW, Lira R, Mullins PB, Navaratnam T, Sakya SM, Stiff CM, Tran TP, Vetelino BC, Xie L, Zhang L, Pustilnik LR, Wood KM, O'Donnell CJ.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2906-11. doi: 10.1016/j.bmcl.2012.02.059. Epub 2012 Mar 1.

PMID:
22429469
5.

Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.

Devadas B, Freeman SK, Zupec ME, Lu HF, Nagarajan SR, Kishore NS, Lodge JK, Kuneman DW, McWherter CA, Vinjamoori DV, Getman DP, Gordon JI, Sikorski JA.

J Med Chem. 1997 Aug 1;40(16):2609-25.

PMID:
9258368
6.

Potent inhibitors of acyl-CoA:cholesterol acyltransferase. 2. Structure-activity relationships of novel N-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)amides.

Kataoka K, Shiota T, Takeyasu T, Minoshima T, Watanabe K, Tanaka H, Mochizuki T, Taneda K, Ota M, Tanabe H, Yamaguchi H.

J Med Chem. 1996 Mar 15;39(6):1262-70.

PMID:
8632433
7.

Synthesis and anticonvulsant activity of some omega-(1H-1-imidazolyl)-N-phenylalkanoic acid amide derivatives.

Aktürk Z, Kiliç F, Erol K, Pabuçcuoğlu V.

Farmaco. 2002 Mar;57(3):201-6.

PMID:
11989798
8.

Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.

Berlin M, Ting PC, Vaccaro WD, Aslanian R, McCormick KD, Lee JF, Albanese MM, Mutahi MW, Piwinski JJ, Shih NY, Duguma L, Solomon DM, Zhou W, Sher R, Favreau L, Bryant M, Korfmacher WA, Nardo C, West RE Jr, Anthes JC, Williams SM, Wu RL, Susan She H, Rivelli MA, Corboz MR, Hey JA.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):989-94. Epub 2005 Nov 15. Erratum in: Bioorg Med Chem Lett. 2006 Jun 15;16(12):3342.

PMID:
16297617
9.

Design, synthesis, and tripeptidyl peptidase II inhibitory activity of a novel series of (S)-2,3-dihydro-2-(4-alkyl-1H-imidazol-2-yl)-1H-indoles.

Breslin HJ, Miskowski TA, Kukla MJ, Leister WH, De Winter HL, Gauthier DA, Somers MV, Peeters DC, Roevens PW.

J Med Chem. 2002 Nov 21;45(24):5303-10.

PMID:
12431057
10.

Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.

Laufer SA, Wagner GK, Kotschenreuther DA, Albrecht W.

J Med Chem. 2003 Jul 17;46(15):3230-44.

PMID:
12852754
11.

Thromboxane synthetase inhibitors and antihypertensive agents. 3. N-[(1H-imidazol-1-yl)alkyl]heteroaryl amides as potent enzyme inhibitors.

Press JB, Wright WB Jr, Chan PS, Haug MF, Marsico JW, Tomcufcik AS.

J Med Chem. 1987 Jun;30(6):1036-40.

PMID:
3585902
12.

Homology model of 1alpha,25-dihydroxyvitamin D3 24-hydroxylase cytochrome P450 24A1 (CYP24A1): active site architecture and ligand binding.

Gomaa MS, Simons C, Brancale A.

J Steroid Biochem Mol Biol. 2007 Apr;104(1-2):53-60. Epub 2007 Jan 19.

PMID:
17240137
13.
14.

Benzofuran- and furan-2-yl-(phenyl)-3-pyridylmethanols: synthesis and inhibition of P450 aromatase.

Saberi MR, Shah K, Simons C.

J Enzyme Inhib Med Chem. 2005 Apr;20(2):135-41.

PMID:
15968818
15.

Synthesis and biological evaluation of imidazole based compounds as cytochrome P-450 inhibitors.

Ahmed S, Smith JH, Nicholls PJ, Whomsley R, Cariuk P.

Drug Des Discov. 1995 Aug;13(1):27-41.

PMID:
8882899
16.
17.

Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl)imidazoles.

Owen CP, Nicholls PJ, Smith HJ, Whomsley R.

J Pharm Pharmacol. 1999 Apr;51(4):427-33.

PMID:
10385215
18.

Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.

Robinson RP, Laird ER, Donahue KM, Lopresti-Morrow LL, Mitchell PG, Reese MR, Reeves LM, Rouch AI, Stam EJ, Yocum SA.

Bioorg Med Chem Lett. 2001 May 7;11(9):1211-3.

PMID:
11354379
19.

Thromboxane synthetase inhibitors and antihypertensive agents. 1. N-[(1H-imidazol-1-yl)alkyl]aryl amides and N-[(1H-1,2,4-triazol-1-yl)alkyl]aryl amides.

Wright WB Jr, Press JB, Chan PS, Marsico JW, Haug MF, Lucas J, Tauber J, Tomcufcik AS.

J Med Chem. 1986 Apr;29(4):523-30.

PMID:
3959030
20.

Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26.

Pautus S, Aboraia AS, Bassett CE, Brancale A, Coogan MP, Simons C.

J Enzyme Inhib Med Chem. 2009 Apr;24(2):487-98. doi: 10.1080/14756360802218334 .

PMID:
18608743
Items per page

Supplemental Content

Write to the Help Desk